trial

Bazedoxifene -Treatment for Women With Schizophrenia

NCTId NCT04113993
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Recruiting
Enrollment 160 (estimated)
Sponsored by The Alfred
Primary completion 2026-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Recruiting
Enrollment
160 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2019-10-07
Primary completion
2026-12-31
Eligibility
FEMALE · 18 Years · 65 Years

Interventions & indications

Drugs
Bazedoxifene Acetate

Sponsors

The AlfredLead Sponsor
Monash UniversityCollaborator

Sites

1 total
Melbourne, Australia

Facts & assertions

4 sourced
Enrollment
160
Phase
PHASE4
Primary Completion Date
2026-12-31
Status
RECRUITING
relationships
The graph out of here
drug
Bazedoxifene Acetate
drug
lead_sponsor
The Alfred
company
collaborator
Monash University
company
indication
Schizo Affective Disorder
indication
Schizophreniform Disorders
indication
Psychotic Disorders
indication